Vital Therapies (VTL) Raised to Hold at BidaskClub
Vital Therapies (NASDAQ:VTL) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
A number of other research firms have also weighed in on VTL. Raymond James Financial reissued a “buy” rating on shares of Vital Therapies in a research report on Tuesday, December 5th. Zacks Investment Research lowered shares of Vital Therapies from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. Finally, ValuEngine raised shares of Vital Therapies from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 21st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. Vital Therapies presently has a consensus rating of “Hold” and an average target price of $6.00.
Vital Therapies (VTL) opened at $5.95 on Wednesday. Vital Therapies has a 12 month low of $2.25 and a 12 month high of $6.70. The firm has a market cap of $272.24, a price-to-earnings ratio of -4.41 and a beta of 5.12.
In other news, Director Muneer A. Satter purchased 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were bought at an average cost of $5.48 per share, with a total value of $548,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Muneer A. Satter purchased 150,000 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The shares were purchased at an average cost of $4.89 per share, for a total transaction of $733,500.00. The disclosure for this purchase can be found here. Insiders have purchased 300,000 shares of company stock worth $1,520,000 over the last three months. 32.60% of the stock is owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can bought a new stake in Vital Therapies in the fourth quarter worth about $118,000. Dimensional Fund Advisors LP bought a new stake in Vital Therapies in the third quarter worth about $116,000. JPMorgan Chase & Co. raised its position in Vital Therapies by 1,985.3% in the third quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock worth $123,000 after acquiring an additional 24,241 shares during the period. New York State Common Retirement Fund bought a new stake in Vital Therapies in the third quarter worth about $213,000. Finally, Dowling & Yahnke LLC bought a new stake in Vital Therapies in the third quarter worth about $252,000. 24.35% of the stock is currently owned by institutional investors.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.